Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559163 | 0.82 | KDM4E (0.50) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL22847567 | 0.80 | LMNA (0.60) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL18561654 | 0.80 | LMNA (0.50) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL11400618 | 0.80 | KDM4E (0.54) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL3558374 | 0.79 | DRD2 (0.41) | LMNACYP1A2GRIA1GRIA2GRIA3 | |
| SCHEMBL28409004 | 0.79 | LMNA (0.59) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL13199362 | 0.79 | LMNA (0.63) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL11093962 | 0.76 | LMNA (0.60) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL3568484 | 0.76 | LMNA (0.52) | LMNAKDM4ECYP1A2GRIA1GRIA2 | |
| SCHEMBL3571705 | 0.76 | KMT2A (0.51) | KDM4ECYP1A2KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3177713-A1 | COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION OF TUMORS | Vindico Nanobiotechnology, LLC. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022805-A1 | COMPOSITIONS AND METHODS FOR INDUCING NANOPARTICLE-MEDIATED MICROVASCULAR EMBOLIZATION OF TUMORS | Vindico NanoBio Technology Inc. (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-2661275-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF HIGH-AFFINITY OXYGEN BINDING AGENTS TO TUMORS | Vindico Nanobio Technology, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| WO-2012094679-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF HIGH-AFFINITY OXYGEN BINDING AGENTS TO TUMORS | Vindico NanoBio Technology Inc. (US) | 2012-07-12 | — | — | WO | disclosed |
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | LMNA 4634/4885KDM4E 2625/4885CYP1A2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.